Sickle cells

Advancing Sickle Cell Disease Awareness, Understanding & Diagnosis

Our Rivipansel (GMI-1070) Evaluating Safety, Efficacy and Time to Discharge (RESET) Phase 3 trial is evaluating an investigational drug (rivipansel) to determine whether it has the potential to reduce time in the hospital and the amount of opioid pain relievers needed for severe sickle cell pain episodes, also known as vaso-occlusive crises. Pfizer is also committed to raising awareness and understanding of SCD, so that people living with the disease will know they are not alone. This includes our continued collaboration with the National Newspaper Publishers Association (NNPA), the development of the Council for Change and supporting the Hospital for Sick Children in Toronto, Canada, and the Korle Bu Teaching Hospital in Ghana, in screening more than 4,500 babies for SCD. As we collaborate to build a model ecosystem of care, Pfizer is also engaging key members of the community in a shared vision: seeing the screening program at Korle Bu serve as a model for other hospitals across Ghana, and in other areas of sub-Saharan Africa.

Go back

Explore Our Innovation